Potential Application of HIF-PH Inhibitors to Treat Kidney Diseases
Frontiers in Bioscience-Landmark · 21.04.2026 · 31 (4)
DOI: 10.31083/fbl47718 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 21.04.2026. Verfasst von Yuichiro Izumi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, 860-8556 Kumamoto, Kumamoto, Japan. Hauptthemen laut MEDLINE: Prolyl-Hydroxylase Inhibitors, Kidney Diseases, Renal Insufficiency, Chronic, Hypoxia-Inducible Factor-Proline Dioxygenases. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors have recently been approved for clinical use in the treatment of renal anemia. HIF-PH inhibitors were developed following studies investigating the role of HIFs and their molecular mechanisms. Unlike erythropoiesis-stimulating agents, these orally administered agents improve renal anemia in patients with chronic kidney disease (CKD) and chronic inflammation. HIF-PH inhibitors improve renal anemia by stabilizing HIF-2α, which increases erythropoietin production. They also improve iron metabolism by suppressing hepcidin and inducing the expression of iron transport-related genes. The renoprotective effects of HIF-PH inhibitors are controversial, owing to the opposing effects of hypoxia-inducible factor 1-alpha (HIF-1α) and hypoxia-inducible factor 2-alpha (HIF-2α) on kidney injury. They induce the expression of both HIF-1α and HIF-2α. HIF-2α plays a key role in erythropoietin production and mitigates CKD. Although HIF-1α contributes to cell survival under hypoxic conditions, its overexpression is suspected to exacerbate kidney injury in CKD. This review summarizes the development of HIF and HIF-PH, from their discovery to the elucidation of their regulatory mechanisms and the development of HIF-PH inhibitors. We reviewed basic research and recently published clinical studies investigating the effects of HIF-PH inhibitors on renal injury, focusing on their clinical use in treating renal injury rather than renal anemia. We discuss the possible benefits of HIF-PH inhibitors used clinically for acute and chronic kidney injury, especially in the advanced stages of CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, 860-8556 Kumamoto, Kumamoto, Japan.
- Department of Physiology, Kitasato University School of Medicine, 252-0374 Sagamihara, Kanagawa, Japan.
- Department of Cardiovascular and Renal Medicine, Hyogo Medical University, 663-8501 Nishinomiya, Hyogo, Japan.
- Nephrology, Internal Medicine, Sagamihara Red-Cross Hospital, 252-0157 Sagamihara, Kanagawa, Japan.
Zitieren
APA
Izumi, Y., Yasuoka, Y., Nanami, M., Kawahara, K., & Nonoguchi, H. (2026). Potential Application of HIF-PH Inhibitors to Treat Kidney Diseases. Frontiers in Bioscience-Landmark, 31(4). https://doi.org/10.31083/fbl47718
Vancouver
Izumi Y, Yasuoka Y, Nanami M, Kawahara K, Nonoguchi H. Potential Application of HIF-PH Inhibitors to Treat Kidney Diseases. Frontiers in Bioscience-Landmark. 2026;31(4). doi:10.31083/fbl47718
BibTeX
@article{Izumi2026,
author = {Izumi, Yuichiro and Yasuoka, Yukiko and Nanami, Masayoshi and Kawahara, Katsumasa and Nonoguchi, Hiroshi},
title = {Potential Application of HIF-PH Inhibitors to Treat Kidney Diseases},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {4},
doi = {10.31083/fbl47718}
}
EUVIMED